Medical Article

Honoring Tom Racobaldo: Crothall CEO to Retire After Decades of Leadership  In 1979, Tom Racobaldo refinished hospital floors and cleaned patient rooms as a Crothall management trainee. Six months later, he received his first assignment: managing a 50-bed hospital with 10 employees in northeast Philadelphia.  Forty-six years later, Racobaldo will retire as Crothall’s chief executive officer. Well-known for his humility, Racobaldo will complete nearly a half-century in the business at the top…

Angelini Pharma’s acquisition of Catalyst Pharmaceuticals is part of a transformation strategy focused on neurological medicines. Catalyst’s top product is Firdapse, the first FDA-approved drug for a particular rare neuromuscular disorder. The post Angelini Pharma’s $4B Acquisition Adds Rare Disease Drugs to a Global Growth Strategy appeared first on MedCity News.

Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology. The post Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer appeared…

Healthtech companies have to navigate a maze of complex regulations, prove their financial model, and win over multiple stakeholders. Finding the right balance between patient protection and innovation is crucial. The post Barriers and Pathways to Healthtech Adoption in Clinical Practice appeared first on MedCity News.

Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…